Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Dermatology"
DOI: 10.1001/jamadermatol.2018.3793
Abstract: Importance Cutaneous lupus erythematosus (CLE) can be severe and treatment resistant. B-cell depletion therapy (BCDT) with rituximab is well recognized in organ involvement in systemic lupus erythematosus (SLE), but its efficacy in cutaneous manifestations is… read more here.
Keywords: cell depletion; response; lupus erythematosus; bilag grade ... See more keywords